Pub Date : 2026-02-06DOI: 10.1016/j.annder.2025.103462
G I Kurmuş, H Kaya Akış, H Karataş, A Gökçe, S P Kartal
{"title":"Tofacitinib-induced paradoxical psoriasis in a patient with ankylosing spondylitis: A case report.","authors":"G I Kurmuş, H Kaya Akış, H Karataş, A Gökçe, S P Kartal","doi":"10.1016/j.annder.2025.103462","DOIUrl":"https://doi.org/10.1016/j.annder.2025.103462","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"103462"},"PeriodicalIF":2.8,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/j.annder.2025.103464
M Alqahtani, M Viguier, G Chaby, G Jeudy, C Bedane, M Alexandre, C Picard-Dahan, S Duvert Lehembre, C Abasq, G Quéreux, H Maillard, J L Perrot, C Couzan, A Pham-Ledard, V Hebert, P Joly
Background: Alleviating sleep disturbances is a key therapeutic goal in pruritic dermatoses. However, sleep disturbance remains under-investigated in patients with bullous pemphigoid (BP), despite contributing to exhaustion in older adults and potentially increasing disease morbidity.
Objectives: To estimate the prevalence and severity of insomnia in BP patients, and examine its correlation with disease activity, self-rated pruritus, and quality of life (QoL).
Method: A national, multicenter, controlled study in 61 BP patients and 61 age- and sex-matched controls. Insomnia severity was assessed via the Insomnia Severity Index (ISI), BP activity via the Bullous Pemphigoid Disease Area Index (BPDAI), and QoL via the Autoimmune Bullous Disease Quality of Life (ABQOL) and ItchyQoL scores. Pruritus severity was rated using a numerical scale (NRS-pruritus). All assessments were repeated after one month of treatment.
Results: Significant sleep disorders (ISI ≥ 15) were observed in 34.4 % of cases and 8.5 % of controls (RR: 4.04; 95 % CI: 1.64-10.06; p = 0.0025). Significant sleep disorder was associated with higher ItchyQoL, ABQOL, and NRS-pruritus scores. However, the ItchyQoL score was the only independent factor (OR = 1.13; 95 % CI: 1.02-1.25). After one month of treatment, significant insomnia decreased by 56.2 % compared to baseline (p < 0.001).
Conclusion: BP is associated with a four-fold risk of insomnia compared to age- and sex-matched controls. Screening for insomnia and promoting sleep quality should be part of BP treatment strategies.
{"title":"Prevalence of sleep disorders in patients with bullous pemphigoid.","authors":"M Alqahtani, M Viguier, G Chaby, G Jeudy, C Bedane, M Alexandre, C Picard-Dahan, S Duvert Lehembre, C Abasq, G Quéreux, H Maillard, J L Perrot, C Couzan, A Pham-Ledard, V Hebert, P Joly","doi":"10.1016/j.annder.2025.103464","DOIUrl":"https://doi.org/10.1016/j.annder.2025.103464","url":null,"abstract":"<p><strong>Background: </strong>Alleviating sleep disturbances is a key therapeutic goal in pruritic dermatoses. However, sleep disturbance remains under-investigated in patients with bullous pemphigoid (BP), despite contributing to exhaustion in older adults and potentially increasing disease morbidity.</p><p><strong>Objectives: </strong>To estimate the prevalence and severity of insomnia in BP patients, and examine its correlation with disease activity, self-rated pruritus, and quality of life (QoL).</p><p><strong>Method: </strong>A national, multicenter, controlled study in 61 BP patients and 61 age- and sex-matched controls. Insomnia severity was assessed via the Insomnia Severity Index (ISI), BP activity via the Bullous Pemphigoid Disease Area Index (BPDAI), and QoL via the Autoimmune Bullous Disease Quality of Life (ABQOL) and ItchyQoL scores. Pruritus severity was rated using a numerical scale (NRS-pruritus). All assessments were repeated after one month of treatment.</p><p><strong>Results: </strong>Significant sleep disorders (ISI ≥ 15) were observed in 34.4 % of cases and 8.5 % of controls (RR: 4.04; 95 % CI: 1.64-10.06; p = 0.0025). Significant sleep disorder was associated with higher ItchyQoL, ABQOL, and NRS-pruritus scores. However, the ItchyQoL score was the only independent factor (OR = 1.13; 95 % CI: 1.02-1.25). After one month of treatment, significant insomnia decreased by 56.2 % compared to baseline (p < 0.001).</p><p><strong>Conclusion: </strong>BP is associated with a four-fold risk of insomnia compared to age- and sex-matched controls. Screening for insomnia and promoting sleep quality should be part of BP treatment strategies.</p>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"103464"},"PeriodicalIF":2.8,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.annder.2025.103466
A Anelli, E Sbidian, J-F Huon, S Valyi, S Barbarot, M Beylot-Barry, C Girard, D Jullien, C Paul, H Aubert
{"title":"Development of a shared decision-making tool for systemic treatment in psoriasis.","authors":"A Anelli, E Sbidian, J-F Huon, S Valyi, S Barbarot, M Beylot-Barry, C Girard, D Jullien, C Paul, H Aubert","doi":"10.1016/j.annder.2025.103466","DOIUrl":"https://doi.org/10.1016/j.annder.2025.103466","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"103466"},"PeriodicalIF":2.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146130930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/j.annder.2025.103461
S. Berros , M. Schollhammer , C. Bocciarelli , G. Le Flahec , N. Kluger , L. Misery , E. Brenaut
{"title":"Pseudolymphoma following laser removal of red tattoo ink","authors":"S. Berros , M. Schollhammer , C. Bocciarelli , G. Le Flahec , N. Kluger , L. Misery , E. Brenaut","doi":"10.1016/j.annder.2025.103461","DOIUrl":"10.1016/j.annder.2025.103461","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103461"},"PeriodicalIF":2.8,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1016/j.annder.2025.103465
R.-A. Henry , V. Pipelart , H. Maillard
{"title":"Progressive mycosis fungoides with ocular involvement and transformation to cerebral T-cell lymphoma: A case report and literature review","authors":"R.-A. Henry , V. Pipelart , H. Maillard","doi":"10.1016/j.annder.2025.103465","DOIUrl":"10.1016/j.annder.2025.103465","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103465"},"PeriodicalIF":2.8,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145964668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1016/j.annder.2025.103463
M. Deriouich , R. Levard , T. Tagmouti , D. Sanogo , J. Cassecuel , A. Khammari , G. Quereux , A. Dompmartin , B. Dreno , J.-M. L’Orphelin
Introduction
Programmed cell death protein (PD)-1 inhibitors can be initiated for stage IIB-IIC melanomas after complete surgical resection following marketing authorization, to reduce the risk of recurrence later in the disease course. A year after this significant change to our therapeutic arsenal in France, we reflect on how this earlier initiation of immunotherapy may influence the practice of the sentinel lymph node biopsy (SLNB) and the overall staging of melanomas, particularly in an era where SLNB is increasingly considered outdated.
The aim of this study is to compare the incidence of de novo IIB-IIC-III melanoma between 2021/2022 and 2023, and to examine the relationship between the stage III incidence and the number of SLN procedures to determine whether this therapeutic change has impacted melanoma staging practices.
Materials and methods
We conducted a retrospective cohort study of 1158 de novo melanomas stage IIB-IIC and III diagnosed between 2021 and 2023. Data were extracted from the RICMEL database, a French, multicenter melanoma registry.
Results
The incidence of SLNB dropped significantly following the marketing authorization of adjuvant anti-PD-1 therapy, decreasing from 59.1 % in 2021/2022 to 38.1 % in 2023 (p < 0.0001). This decline was accompanied by a significant shift in the staging of IIB-IIC-III melanomas.
Conclusion
Although prognostic scores or new marketing authorization could suggest performing fewer SLNBs, the reduced use of SLNB due to earlier access to immunotherapy may result in inaccurate melanoma staging, potentially affecting prognosis and treatment decisions.
{"title":"Evolution of the sentinel lymph node procedure following the approval of adjuvant anti-PD-1 therapy for stage IIB and IIC melanoma: A multicenter study from RICMEL database","authors":"M. Deriouich , R. Levard , T. Tagmouti , D. Sanogo , J. Cassecuel , A. Khammari , G. Quereux , A. Dompmartin , B. Dreno , J.-M. L’Orphelin","doi":"10.1016/j.annder.2025.103463","DOIUrl":"10.1016/j.annder.2025.103463","url":null,"abstract":"<div><h3>Introduction</h3><div>Programmed cell death protein (PD)-1 inhibitors can be initiated for stage IIB<del>-</del>IIC melanomas after complete surgical resection following marketing authorization, to reduce the risk of recurrence later in the disease course. A year after this significant change to our therapeutic arsenal in France, we reflect on how this earlier initiation of immunotherapy may influence the practice of the sentinel lymph node biopsy (SLNB) and the overall staging of melanomas, particularly in an era where SLNB is increasingly considered outdated.</div><div>The aim of this study is to compare the incidence of <em>de novo</em> IIB<del>-</del>IIC<del>-</del>III melanoma between 2021/2022 and 2023, and to examine the relationship between the stage III incidence and the number of SLN procedures to determine whether this therapeutic change has impacted melanoma staging practices.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective cohort study of 1158 <em>de novo</em> melanomas stage IIB<del>-</del>IIC and III diagnosed between 2021 and 2023. Data were extracted from the RICMEL database, a French, multicenter melanoma registry.</div></div><div><h3>Results</h3><div>The incidence of SLNB dropped significantly following the marketing authorization of adjuvant anti-PD-1 therapy, decreasing from 59.1 % in 2021/2022 to 38.1 % in 2023 (p < 0.0001). This decline was accompanied by a significant shift in the staging of IIB-IIC-III melanomas.</div></div><div><h3>Conclusion</h3><div>Although prognostic scores or new marketing authorization could suggest performing fewer SLNBs, the reduced use of SLNB due to earlier access to immunotherapy may result in inaccurate melanoma staging, potentially affecting prognosis and treatment decisions.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103463"},"PeriodicalIF":2.8,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145964640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1016/j.annder.2025.103440
L. Martin , W. Spiering , K. Aelbrecht , T. Aranyi , C. Duranton , N. Kiss , E. Letavernier , M. Medvecz , M. Pfau , P.I. Nevalainen , L. Nollet , V. Murro , F. Szeri , S. Väärämäki , G. Leftheriotis , O.M. Vanakker
Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder described more than 150 years ago in which calcification and fragmentation of the elastic fibers result in a variety of symptoms which differ greatly in presentation and severity between patients. The diagnosis of PXE can still be made in many patients based on clinical presentation. However, in the advent of genetic screening that followed upon the identification of the first causal gene, ABCC6, milder cases of PXE or patients with a less typical onset of disease surfaced. Moreover, it became clear in the last years that PXE has at least one allelic disorder which can also result from (identical) ABCC6 or ENPP1 pathogenic variants, namely generalized arterial calcification of infancy (GACI). These recent evolutions lead to challenges in making the correct diagnosis in a given number of patients. As emerging possibilities to treat PXE require a definite diagnosis, a critical re-appraisal of the diagnostic criteria for PXE − taking into account new clinical, biochemical and molecular characteristics – appeared to be necessary.
The REACT-PXE (Research, Education and Advanced Care Teams for PXE) Consortium − gathering most European experts on PXE − has been established to take on this task as a first step in updating the management of PXE. This paper presents an updated, evidence-based definition of PXE, revised diagnostic criteria, “red flags” for considering PXE, and a patient-centered approach to identifying meaningful outcomes. All skin, ocular, vascular and other disease manifestations are addressed and illustrated, followed by specific chapters on molecular genetics and biological alterations. All these efforts are designed to improve disease management, consider future treatment for all patients, with or without molecular definition of their condition, enhance patient care, and inform for future research directions.
{"title":"REACT-PXE: a consensus on diagnosis and future research concerning pseudoxanthoma elasticum (PXE)","authors":"L. Martin , W. Spiering , K. Aelbrecht , T. Aranyi , C. Duranton , N. Kiss , E. Letavernier , M. Medvecz , M. Pfau , P.I. Nevalainen , L. Nollet , V. Murro , F. Szeri , S. Väärämäki , G. Leftheriotis , O.M. Vanakker","doi":"10.1016/j.annder.2025.103440","DOIUrl":"10.1016/j.annder.2025.103440","url":null,"abstract":"<div><div>Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder described more than 150 years ago in which calcification and fragmentation of the elastic fibers result in a variety of symptoms which differ greatly in presentation and severity between patients. The diagnosis of PXE can still be made in many patients based on clinical presentation. However, in the advent of genetic screening that followed upon the identification of the first causal gene, <em>ABCC6,</em> milder cases of PXE or patients with a less typical onset of disease surfaced. Moreover, it became clear in the last years that PXE has at least one allelic disorder which can also result from (identical) <em>ABCC6</em> or <em>ENPP1</em> pathogenic variants, namely generalized arterial calcification of infancy (GACI). These recent evolutions lead to challenges in making the correct diagnosis in a given number of patients. As emerging possibilities to treat PXE require a definite diagnosis, a critical re-appraisal of the diagnostic criteria for PXE − taking into account new clinical, biochemical and molecular characteristics – appeared to be necessary.</div><div>The REACT-PXE (Research, Education and Advanced Care Teams for PXE) Consortium − gathering most European experts on PXE − has been established to take on this task as a first step in updating the management of PXE. This paper presents an updated, evidence-based definition of PXE, revised diagnostic criteria, “red flags” for considering PXE, and a patient-centered approach to identifying meaningful outcomes. All skin, ocular, vascular and other disease manifestations are addressed and illustrated, followed by specific chapters on molecular genetics and biological alterations. All these efforts are designed to improve disease management, consider future treatment for all patients, with or without molecular definition of their condition, enhance patient care, and inform for future research directions.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103440"},"PeriodicalIF":2.8,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1016/j.annder.2025.103419
H. Dufresne , C. Godot , J. Mashiah , S. Dimarcq , C. Bodemer , S. Hadj-Rabia
Background
Therapeutic patient education (TPE) in pediatrics is part of the healthcare pathway, from diagnosis in childhood to adulthood. The COVID-19 pandemic accelerated the development of digital TPE. The framework for digital TPE (e-TPE) remains to be defined.
Objectives
Suggest key points for organizing and running e-TPE programs.
Patients and methods
A monocentric prospective study was conducted in adolescents with a chronic skin disease, as well as their parents and healthcare professionals participating in an e-TPE program. Participants answered open questions either during a one-on-one session (patients and parents) or via a questionnaire (healthcare professionals).
Results
Twenty-three parents were included: eleven adolescents and sixteen healthcare professionals. Parents, patients, and healthcare professionals showed a preference for remote TPE sessions. The familiar home environment facilitates the learning process. However, professional access to privacy can be a source of discomfort. The technical aspect presents a major obstacle for both healthcare professionals and parents.
Discussion and conclusion
Access to TPE is enhanced by e-tools, which facilitate the participation of parents, expert patient partners, associations, and other professionals. Travel costs and possible scheduling conflicts are easily overcome, further harmonizing care. In this way, remote TPE sessions should enhance the development of the city-hospital network. Importantly, participant age is a key point in terms of screen time (age < 6 years), concentration/remobilization in front of a computer screen (age < 10 years), technical difficulties, and digital illiteracy (across the entire population). Confidentiality, parental information, and invasion of privacy must be considered.
{"title":"Therapeutic patient education through digital technology: Recommendations for paediatrics and dermatology","authors":"H. Dufresne , C. Godot , J. Mashiah , S. Dimarcq , C. Bodemer , S. Hadj-Rabia","doi":"10.1016/j.annder.2025.103419","DOIUrl":"10.1016/j.annder.2025.103419","url":null,"abstract":"<div><h3>Background</h3><div>Therapeutic patient education (TPE) in pediatrics is part of the healthcare pathway, from diagnosis in childhood to adulthood. The COVID-19 pandemic accelerated the development of digital TPE. The framework for digital TPE (e-TPE) remains to be defined.</div></div><div><h3>Objectives</h3><div>Suggest key points for organizing and running e-TPE programs.</div></div><div><h3>Patients and methods</h3><div>A monocentric prospective study was conducted in adolescents with a chronic skin disease, as well as their parents and healthcare professionals participating in an e-TPE program. Participants answered open questions either during a one-on-one session (patients and parents) or via a questionnaire (healthcare professionals).</div></div><div><h3>Results</h3><div>Twenty-three parents were included: eleven adolescents and sixteen healthcare professionals. Parents, patients, and healthcare professionals showed a preference for remote TPE sessions. The familiar home environment facilitates the learning process. However, professional access to privacy can be a source of discomfort. The technical aspect presents a major obstacle for both healthcare professionals and parents.</div></div><div><h3>Discussion and conclusion</h3><div>Access to TPE is enhanced by e-tools, which facilitate the participation of parents, expert patient partners, associations, and other professionals. Travel costs and possible scheduling conflicts are easily overcome, further harmonizing care. In this way, remote TPE sessions should enhance the development of the city-hospital network. Importantly, participant age is a key point in terms of screen time (age < 6 years), concentration/remobilization in front of a computer screen (age < 10 years), technical difficulties, and digital illiteracy (across the entire population). Confidentiality, parental information, and invasion of privacy must be considered.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103419"},"PeriodicalIF":2.8,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号